Cabaletta Bio, Inc. (CABA)
NASDAQ: CABA · Real-Time Price · USD
1.280
+0.010 (0.79%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Cabaletta Bio Employees
As of December 31, 2024, Cabaletta Bio had 164 total employees, including 161 full-time and 3 part-time employees. The number of employees increased by 61 or 59.22% compared to the previous year.
Employees
164
Change (1Y)
61
Growth (1Y)
59.22%
Revenue / Employee
n/a
Profits / Employee
-$706,488
Market Cap
64.44M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CABA News
- 27 days ago - Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform - Business Wire
- 2 months ago - Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings - GlobeNewsWire
- 2 months ago - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings - GlobeNewsWire
- 2 months ago - Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February - GlobeNewsWire
- 3 months ago - Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference - GlobeNewsWire
- 3 months ago - Cabaletta Bio: Finding Optimism In Dire Straits - Seeking Alpha